×
About 1,198 results

ALLMedicine™ Oral Medicine Center

Research & Reviews  343 results

Importance of the vaporization margin during CO2 laser treatment of oral leukoplakia, a...
https://doi.org/10.1111/odi.14345
Oral Diseases; Vilar-Villanueva M, Somoza-Martín JM et. al.

Aug 10th, 2022 - The main purpose of this study was to assess the response of oral leukoplakia to CO2 laser vaporization treatment, as well as determining possible factors that may affect recurrence of lesions. A retrospective study was conducted, in which the med...

The Prevalence of Gingival Pigmentation Among a Sample of Adult Egyptian Population.
https://clinicaltrials.gov/ct2/show/NCT05453890

Jul 12th, 2022 - Dental patients will be recruited in a consecutive manner from the diagnostic center, Faculty of Dentistry, Cairo University. Medical history will be taken and patients with certain diseases as Addison's disease, Albright's syndrome, Hereditary he...

Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practit...
https://doi.org/10.1111/odi.14301
Oral Diseases; Pentenero M, Sutera S et. al.

Jul 7th, 2022 - The management of oral potentially malignant disorders (OPMD) including oral leukoplakia (OL) is not currently structured according to agreed guidelines. The current report presents survey data gathered from Oral Medicine Practitioners (OMPs) in E...

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
https://clinicaltrials.gov/ct2/show/NCT01639508

Jun 23rd, 2022 - The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study look...

MASCC/ISOO expert opinion on the management of oral problems in patients with advanced ...
https://doi.org/10.1007/s00520-022-07211-2
Supportive Care in Cancer : Official Journal of the Multi... Jones JA, Chavarri-Guerra Y et. al.

Jun 19th, 2022 - The Palliative Care Study Group in conjunction with the Oral Care Study Group of the Multinational Association for Supportive Care in Cancer (MASCC) formed a sub-group to develop evidence-based guidance on the management of common oral problems in...

see more →

Guidelines  2 results

Classifying orofacial pains: a new proposal of taxonomy based on ontology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383028
Journal of Oral Rehabilitation; Nixdorf DR, Drangsholt MT et. al.

Aug 19th, 2011 - We propose a new taxonomy model based on ontological principles for disorders that manifest themselves through the symptom of persistent orofacial pain and are commonly seen in clinical practice and difficult to manage. Consensus meeting of eight ...

The dental treatment of patients with joint replacements: a position paper from the Ame...
https://doi.org/10.14219/jada.archive.2010.0255
Journal of the American Dental Association (1939); Little JW, Jacobson JJ et. al.

Jun 3rd, 2010 - In February 2009, the American Academy of Orthopaedic Surgeons (AAOS) published an information statement in which the organization "recommends that clinicians consider antibiotic prophylaxis [AP] for all total joint replacement patients prior to a...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  87 results

The Prevalence of Gingival Pigmentation Among a Sample of Adult Egyptian Population.
https://clinicaltrials.gov/ct2/show/NCT05453890

Jul 12th, 2022 - Dental patients will be recruited in a consecutive manner from the diagnostic center, Faculty of Dentistry, Cairo University. Medical history will be taken and patients with certain diseases as Addison's disease, Albright's syndrome, Hereditary he...

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
https://clinicaltrials.gov/ct2/show/NCT01639508

Jun 23rd, 2022 - The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study look...

The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome
https://clinicaltrials.gov/ct2/show/NCT05309070

May 25th, 2022 - The research will include patients who come to the Department of Oral Medicine at the Faculty of Dentistry in Zagreb, and who have been diagnosed with burning mouth syndrome. It is planned to gather a total of 60 patients, 30 patients in the treat...

Role of the Dentist in the Control of the Alcoholic Habit in Patients With Potentially Malignant Oral Lesions
https://clinicaltrials.gov/ct2/show/NCT04584333

May 18th, 2022 - Introduction: Alcohol is the most consumed psychoactive substance, its consumption is very prevalent and there is a low perception of the risk it poses in our society. Alcohol is a risk factor and a causal factor for multiple pathologies, includin...

Effectiveness of Zinc Supplementation in Management of Patients With Symptomatic Benign Migratory Glossitis
https://clinicaltrials.gov/ct2/show/NCT05190562

May 17th, 2022 - Forty-eight patients diagnosed with symptomatic benign migratory glossitis will be selected from Oral Medicine, Periodontology and Oral Diagnosis department, Faculty of dentistry, Ain shams university. Research ethical committee will review the pr...

see more →

News  37 results

Pfizer Says COVID-19 Pill Near 90% Effective in Final Analysis
https://www.medscape.com/viewarticle/964750

Dec 14th, 2021 - NEW YORK (Reuters) - Pfizer Inc on Tuesday said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effecti...

Managing Mouth Sores in Patients with Breast Cancer
https://www.onclive.com/view/managing-mouth-sores-in-patients-with-breast-cancer

Apr 2nd, 2021 - Transcript:Adam M. Brufsky, MD: Right. So the last thing we’ll talk about in terms of these targeted therapies is we have one that’s already been approved. Where does it fit in now, I guess it’s the old school one, this is old school which is ever...

Infection Prophylaxis in Acute Myeloid Leukemia
https://www.onclive.com/view/infection-prophylaxis-in-acute-myeloid-leukemia

Apr 2nd, 2021 - Transcript:Ruben A. Mesa, MD, FACP: Rafael, clearly there’s a lot of guidance out there to try to help with giving guidance, and I do tend to agree with Elias that there’s really nothing standard about AML therapy and that it really needs people w...

Drug Revenues May Migrate to Specialty Pharma
https://www.onclive.com/view/drug-revenues-may-migrate-to-specialty-pharma

Dec 5th, 2020 - Kevin Colgan The rising number of oral oncology drugs that can be supplied through pharmacy networks rather than administered in clinical settings, such as intravenous drugs, has many physicians worried that they are losing control of an importan...

ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLC
https://www.onclive.com/view/asco-new-data-for-alecensa-shows-5year-overall-survival-in-alkpositive-nsclc

Dec 4th, 2020 - On Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study. The updated data show an increased 5-year survival rate with Alecensa® (alectinib) compared with crizotinib, ...

see more →